Document Detail


Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.
MedLine Citation:
PMID:  19509556     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of this prospective study was to compare the sensitivities and the specificities of combined 2-(F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (PET/CT), abdominal/transvaginal ultrasound (US), and CT for diagnosing recurrent ovarian cancer (OC) and to evaluate the influence of PET/CT on referral of patients with solitary recurrence to secondary cytoreductive surgery. From April 2005 to November 2007, 60 patients were consecutively included to PET/CT 68 times. The inclusion criteria were remission of 3 months or longer and recurrent OC suspected from physical examination, US, or increasing cancer antigen 125 (CA125) level (>50 U/mL or >15% above baseline level). Recurrent OC was diagnosed 58 times in 52 patients. The sensitivities of US, CT, and PET/CT for diagnosing recurrence were 66% (P = 0.003), 81% (P = 0.0001), and 97% (P < 0.0001), respectively. The specificity of US, CT, and PET/CT for diagnosing recurrence was 90%. Positron emission tomography/CT diagnosed recurrence in 19 (66%) of 29 patients without recurrence according to US and in 10 (50%) of 20 patients without recurrence after CT. Multiple recurrent tumors were found using PET/CT in 27 (69%) of 39 patients with solitary tumors on US and in 8 (42%) of 19 patients with solitary tumors on CT. We conclude that the diagnostic value of PET/CT for detecting recurrent OC was higher than those of US and CT and that PET/CT more accurately identified patients with solitary recurrence. However, prospective clinical trials are needed to specify the characteristics of patients most likely to undergo complete secondary surgery and to further clarify the role of PET/CT in selecting patients for secondary surgery.
Authors:
Signe Risum; Claus Høgdall; Elena Markova; Anne K Berthelsen; Annika Loft; Flemming Jensen; Estrid Høgdall; Henrik Roed; Svend A Engelholm
Related Documents :
10605586 - The diagnostic value of positron emission tomography (pet) with radiolabelled fluorodeo...
16427246 - Whole body mr imaging: applications in oncology.
18328726 - The decision to operate: role of integrated computed tomography positron emission tomog...
19464906 - Preoperative intrathoracic lymph node staging in patients with non-small-cell lung canc...
22122126 - Amelioration of caudal thoracic syringohydromyelia following surgical management of an ...
12591666 - Mr imaging features of osteochondritis dissecans of the femoral sulcus.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society     Volume:  19     ISSN:  1525-1438     ISO Abbreviation:  Int. J. Gynecol. Cancer     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-06-10     Completed Date:  2009-09-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111626     Medline TA:  Int J Gynecol Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  600-4     Citation Subset:  IM    
Affiliation:
Department of Oncology, Finsen Center, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. signerisum@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Female
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Middle Aged
Neoplasm Recurrence, Local / radionuclide imaging*,  surgery*,  ultrasonography
Ovarian Neoplasms / radionuclide imaging*,  surgery*,  ultrasonography
Positron-Emission Tomography / methods
Prospective Studies
Radiopharmaceuticals / diagnostic use*
Sensitivity and Specificity
Tomography, X-Ray Computed
Young Adult
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reasons for improved survival from ovarian cancer in New South Wales, Australia, between 1980 and 20...
Next Document:  Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer.